Phenytoin alters transcript levels of hormone-sensitive lipase in muscle from horses with hyperkalemic periodic paralysis.

This study explores how phenytoin, a treatment, impacts the transcription levels of specific proteins relating to fatty acid metabolism in horses affected by hyperkalemic periodic paralysis, a muscle disorder. It reveals that this medication can selectively increase hormone sensitive lipase transcript levels, potentially revealing a secondary effect of the disorder and a therapeutic action of phenytoin.

Hyperkalemic Periodic Paralysis and Fatty Acid Metabolism

• The research focuses on a condition known as hyperkalemic periodic paralysis (HyperPP) in horses. This ailment is marked by episodic muscle weakness or paralysis and is known to be linked with a defect in the sodium channel.
• It seems this primary defect in the sodium channel could be tied to a secondary alteration in triacylglycerol-associated fatty acid metabolism (TAFAM) within skeletal muscle. TAFAM essentially involves the breakdown and use of fats for energy within the body.
• Researchers hypothesize that TAFAM may also be involved in how the drug phenytoin acts therapeutically to treat HyperPP.

Role of Phenytoin in Treating HyperPP

• The study examines the effects of phenytoin on the transcript levels of three key proteins involved in TAFAM. These proteins are the hormone sensitive lipase (HSL), carnitine palmitoyltransferase (CPT), and fatty acid binding protein (FABP).
• These transcript levels were quantified using a process known as competitive reverse transcription polymerase chain reaction. The process was completed in undifferentiated and differentiated primary cultures of equine skeletal muscle. These samples were gathered from control horses, and both heterozygous and homozygous-affected HyperPP horses.

Findings and Conclusions

• The primary finding of the study was a much lower level of HSL transcript in both sets of muscle cultures from horses homozygous-affected by HyperPP when compared to horses of other genotypes.
• The administration of phenytoin led to a selective increase in the HSL transcript within cultures from homozygous-affected horses to levels comparable to those seen in control horses and heterozygous-affected horses.
• The transcript levels for CPT and FABP showed no significant difference based on genotype, differentiation of muscle cultures, or phenytoin treatment.
• The results imply that the primary defect present in HyperPP may also lead to a decrease in HSL transcript levels. This indicates that the therapeutic action of phenytoin potentially includes the regulation of mRNA transcripts in skeletal muscle.